Leerink Partners Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $110

Benzinga Newsdesk www.benzinga.com Positive 93.6%

Neg 0% Neu 0% Pos 93.6%

Leerink Partners analyst Faisal Khurshid maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $107 to $110.